Open Access<p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>
Author(s) -
Eddie Gibson,
Najida Begum,
Ian Koblbauer,
George Dranitsaris,
Danny Liew,
Phil McEwan,
Yong Yuan,
A. Juarez-Garcia,
David Tyas,
Clive Pritchard
Publication year - 2020
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s238725
Subject(s) - medicine , ipilimumab , oncology , progression free survival , regimen , clinical trial , nivolumab , metastatic melanoma , cancer , overall survival , immunotherapy
Existing economic model frameworks may not adequately capture the atypical treatment response patterns in immuno-oncology (I-O) compared with conventional therapies and thus may fail to represent the full clinical value associated with disease dynamics and improved survival.